These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 11577556)

  • 1. Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy.
    Valenta R; Vrtala S; Focke-Tejkl M; Twardosz A; Swoboda I; Bugajska-Schretter A; Spitzauer S; Kraft D
    Clin Allergy Immunol; 2002; 16():495-517. PubMed ID: 11577556
    [No Abstract]   [Full Text] [Related]  

  • 2. Allergen-specific immunotherapy.
    Niederberger V
    Immunol Lett; 2009 Feb; 122(2):131-3. PubMed ID: 19100771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering allergens.
    Mutschlechner S; Ferreira F
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):226-9. PubMed ID: 17124778
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of antigen-specific immunotherapy of allergy.
    Valenta R
    Nat Rev Immunol; 2002 Jun; 2(6):446-53. PubMed ID: 12093011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
    Valenta R; Linhart B; Swoboda I; Niederberger V
    Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.
    Valenta R; Vrtala S; Focke-Tejkl M; Bugajska-Schretter ; Ball T; Twardosz A; Spitzauer S; Grönlund H; Kraft D
    Biol Chem; 1999; 380(7-8):815-24. PubMed ID: 10494830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New concepts in therapy of type I allergic diseases].
    Valenta R; Steinberger P; Vrtala S; Grote M; Laffer S; Sperr WR; Valent P; Kraft D; Scheiner O
    Wien Klin Wochenschr; 1993; 105(23):682-6. PubMed ID: 7508663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R
    Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of engineered allergen-specific immunotherapy vaccines.
    Focke-Tejkl M; Valenta R
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):555-63. PubMed ID: 22885888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic engineering of pollen allergens for hayfever immunotherapy.
    Bhalla PL
    Expert Rev Vaccines; 2003 Feb; 2(1):75-84. PubMed ID: 12901599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening.
    Thalhamer T; Dobias H; Stepanoska T; Pröll M; Stutz H; Dissertori O; Lackner P; Ferreira F; Wallner M; Thalhamer J; Hartl A
    J Allergy Clin Immunol; 2010 Apr; 125(4):926-934.e10. PubMed ID: 20371399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy.
    González-Rioja R; Ibarrola I; Arilla MC; Ferrer A; Mir A; Andreu C; Martínez A; Asturias JA
    J Allergy Clin Immunol; 2007 Sep; 120(3):602-9. PubMed ID: 17561242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological responses to allergen immunotherapy.
    Till SJ; Durham SR
    Clin Allergy Immunol; 2004; 18():85-104. PubMed ID: 15042910
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanisms of allergen-specific immunotherapy.
    Akdis CA; Blaser K
    Allergy; 2000 Jun; 55(6):522-30. PubMed ID: 10858982
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetically modified allergens.
    Niederberger V; Valenta R
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):727-38. PubMed ID: 15474868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual vaccines based on wild-type recombinant allergens.
    Van Overtvelt L; Razafindratsita A; St-Lu N; Didierlaurent A; Batard T; Lombardi V; Martin E; Moingeon P
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):247-9. PubMed ID: 17124785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy.
    Möbs C; Slotosch C; Löffler H; Pfutzner W; Hertl M
    Int Arch Allergy Immunol; 2008; 147(3):171-8. PubMed ID: 18594146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.